We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced that it has signed a collaboration deal with Infinity Pharmaceuticals to evaluate the combination of its PD-1 inhibitor, Opdivo, and the latter’s investigational immunotherapy, IPI-549, for the treatment of advanced urothelial cancer, a type of bladder cancer.
Infinity will conduct and operate the study. The phase II MARIO-275 study will enroll approximately 150 patients that will compare the Opdivo + IPI-549 combo with Opdivo alone in advanced urothelial cancer patients, whose disease has progressed or recurred following treatment with platinum-based chemotherapy. The study’s primary endpoint will be its overall response rate.
Per the company, the main idea of the study is to check whether targeting the tumor microenvironment with IPI-549 will increase the activity of Opdivo for subjects with urothelial cancer.
The evaluation is expected to start in the first half of 2019. Notably, the combination drugs are already being examined in a phase I/Ib study on patients with advanced solid tumors.
Bristol-Myers’ clinical study collaboration with Infinity to assess the IPI-549/Opdivo combination bodes well for the former.
Opdivo gained a regulatory nod for the first indication in July 2014. It is currently approved across several countries for several cancer indications. Potential approval for other diseases will further boost prospects of this blockbuster drug.
Opdivo retained its impressive performance with sales surging 42% year over year to $1.79 billion. Evidently, it became the top revenue generator for the company in third-quarter 2018.
In October, Bristol-Myers announced that it has entered into a clinical trial agreement with Compugen (CGEN - Free Report) . Per the deal, both companies will evaluate the safety and tolerability of Compugen's COM701, an investigational antibody, combined with Opdivo for treating patients afflicted with advanced solid tumors.
Bristol-Myers has deals inked with several other research institutes plus small and large biotech as well as pharma giants for studying Opdivo in combination with their cancer treatments. The leading names include Johns Hopkins University, Johnson & Johnson (JNJ - Free Report) AbbVie, Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics among others.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
Bristol-Myers Squibb Company (BMY - Free Report) announced that it has signed a collaboration deal with Infinity Pharmaceuticals to evaluate the combination of its PD-1 inhibitor, Opdivo, and the latter’s investigational immunotherapy, IPI-549, for the treatment of advanced urothelial cancer, a type of bladder cancer.
Infinity will conduct and operate the study. The phase II MARIO-275 study will enroll approximately 150 patients that will compare the Opdivo + IPI-549 combo with Opdivo alone in advanced urothelial cancer patients, whose disease has progressed or recurred following treatment with platinum-based chemotherapy. The study’s primary endpoint will be its overall response rate.
Per the company, the main idea of the study is to check whether targeting the tumor microenvironment with IPI-549 will increase the activity of Opdivo for subjects with urothelial cancer.
The evaluation is expected to start in the first half of 2019. Notably, the combination drugs are already being examined in a phase I/Ib study on patients with advanced solid tumors.
Bristol-Myers’ clinical study collaboration with Infinity to assess the IPI-549/Opdivo combination bodes well for the former.
Opdivo gained a regulatory nod for the first indication in July 2014. It is currently approved across several countries for several cancer indications. Potential approval for other diseases will further boost prospects of this blockbuster drug.
Opdivo retained its impressive performance with sales surging 42% year over year to $1.79 billion. Evidently, it became the top revenue generator for the company in third-quarter 2018.
In October, Bristol-Myers announced that it has entered into a clinical trial agreement with Compugen (CGEN - Free Report) . Per the deal, both companies will evaluate the safety and tolerability of Compugen's COM701, an investigational antibody, combined with Opdivo for treating patients afflicted with advanced solid tumors.
Bristol-Myers has deals inked with several other research institutes plus small and large biotech as well as pharma giants for studying Opdivo in combination with their cancer treatments. The leading names include Johns Hopkins University, Johnson & Johnson (JNJ - Free Report) AbbVie, Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics among others.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>